Gastroesophageal Adenocarcinoma Market Research Report 2026, Competitive Analysis of ALX Oncology, Merck, AstraZeneca, BeOne Medicines, Taiho Pharmaceuticals, Eli Lilly - Global Forecast t...
ALX Oncology Holdings Inc. (ALXO)
Company Research
Source: Yahoo! Finance
junction, is on the rise due to risk factors like GERD, obesity, and smoking. This aggressive cancer is often diagnosed at advanced stages, complicating treatment and worsening prognosis. Market growth is driven by the aging population and lifestyle-related risks, boosting demand for diagnostics and therapies. Leading companies like Merck and AstraZeneca are advancing GEA treatment with innovations in targeted and immune therapies. Challenges persist, including high treatment costs and delayed diagnosis, hindering effective care globally. Dublin, April 28, 2026 (GLOBE NEWSWIRE) -- The "Gastroesophageal Adenocarcinoma Market - A Global and Regional Analysis: Focus on Country, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global gastroesophageal adenocarcinoma market is highly competitive, with several leading companies driving innovation and market growth. Companies such as ALX Oncology Inc., Merck & Co., AstraZeneca, BeOne Medicines, Ltd, Taiho Pharmac
Show less
Read more
Impact Snapshot
Event Time:
ALXO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALXO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALXO alerts
High impacting ALX Oncology Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ALXO
News
- ALX Oncology (ALXO) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ALXO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to MarketBeat
- ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules [Yahoo! Finance]Yahoo! Finance
- ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing RulesGlobeNewswire
- ALX Oncology Appoints Jeff Knight as Chief Development and Operating OfficerGlobeNewswire
- ALX Oncology (ALXO) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $5.00 price target on the stock.MarketBeat
ALXO
Earnings
- 2/27/26 - Miss
ALXO
Sec Filings
- 4/28/26 - Form SCHEDULE
- 4/20/26 - Form ARS
- 4/20/26 - Form DEF
- ALXO's page on the SEC website